Jeffrey Kindler news from FierceBiotech
News
SPOTLIGHT: Investors, analysts not impressed with Pfizer
Investors and analysts are none too impressed with Pfizer's new strategies as outlined by CEO Jeffrey Kindler and other execs during an annual Wall Street update yesterday. The stock fell to within Read more...
SPOTLIGHT: Is Pfizer's CEO as bold as promised?
Like natives encountering a strange explorer in an old B movie, investors hailed Jeffrey Kindler (photo) when he was picked to succeed Pfizer CEO Read more...
Pfizer hires new R&D chief, launches biotech center
Pfizer is making moves to salvage its troubled pipeline. The company has named Martin Mackay as its new Read more...
Pfizer shows the door to two top executives
Jeffrey Kindler's plans to shake up Pfizer have led to the departure of two top executives. John LaMattina, global head of research, will retire and Alan Levin resigned as chief financial officer, Read more...
Pfizer's Kindler leaves analysts feeling flat
Wall Street's eyes were focused on Jeffrey Kindler today as Pfizer's new CEO stepped up to unveil its quarterly profits. Those profits soared 112 percent on increased drug revenue. But Pfizer now Read more...
Get more Jeffrey Kindler coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets